About Prescient: Your strategy-to-impact partner

We are a strategic advisory partner that transforms complex clinical and commercial intelligence into actionable strategies, helping global biopharma teams maximize asset value and minimize market risk. 


Why biopharma leaders choose Prescient

Peer-to-peer scientific literacy

Led by former industry leaders 

The power of positive challenge 

Integrated lifecycle advisory 

With over half our team holding MDs, PhDs or advanced scientific degrees, we engage as intellectual peers who understand your asset's science as deeply as you do. 

Your projects are guided by senior experts who bring real-world operational experience rather than just theoretical frameworks. 

We bring bold, constructive challenge to your strategy to help you uncover hidden risks and blind spots before the market does. 

We deliver joined-up thinking by seamlessly connecting customer insights, competitor assessment, medical strategy and market access.

News and Insights

Explore our latest insights, whitepapers, and event highlights to learn more about the latest developments and perspectives shaping the evolving healthcare landscape.

Discover all
Blog

Why Pharma Needs Connected Intelligence

Find out more
Blog

From Data-Rich to Decision-Ready: Why Earlier, Faster Integration of Insights Now Matters More Than Ever

Find out more

Our people: The experts behind your strategy

Great strategy is only as strong as the team behind it. At Prescient, you partner directly with senior specialists who combine deep subject matter expertise with a truly global perspective. 

Our global scale and reach: 

  • 550+ pharma experts in the UK, US and globally 
  • 30+ languages 
  • 25+ nationalities  
  • 8 locations 
  • >50% MDs, PhDs, relevant scientific degrees 

Maxine Smith

Head of Practice Partner

Simon Campling

Head of Practice Partner

Sanam Sikander-Rehman

Associate Partner, Co-Lead Medical

Cameron Mackenzie

Client Partner

How we partner

We build deep, sustained relationships to help you cut through complexity and turn stronger decisions into measurable business impact across the asset lifecycle. 

This practical execution is how we maintain an 85% recurrent business rate and average 7 years of continuous partnership with top-tier global biopharma companies. 

Looking to the future

We are taking immediate action to minimize our carbon footprint and mitigate our impact. Our Environmental, Social and Governance (ESG) program outlines our commitment to making responsible decisions for the future of our communities and our planet. 

Ready to turn strategy into measurable impact?

The life sciences landscape is full of complexity, but you don't have to navigate it alone. As your strategy-to-impact partner, we are here to help you see further, go deeper and deliver impact where it counts.

Connect with our experts